|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.72 SEK | -2.26% |
|
+26.24% | -34.87% |
| 06-23 | Citadel Back as Public Short Seller in Synact Pharma | FW |
| 06-18 | Edison Maintains Its Valuation for Synact Pharma After Trial Results | FW |
| Market Cap | 801M 82.12M 72.3M 66.69M 62.37M 117M 7.74B 119M 310M 3.82B 308M 302M 13.28B | P/E 2026 * |
-10.1x | P/E 2027 * | -19.8x |
|---|---|---|---|---|---|
| Enterprise Value | 784M 80.33M 70.72M 65.23M 61.01M 114M 7.57B 116M 304M 3.74B 302M 295M 12.99B | EV / Sales 2026 * |
5.65x | EV / Sales 2027 * | 39.1x |
| Free-Float |
70.28% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: SynAct Pharma AB
| 1 day | -2.26% | ||
| 1 week | +26.24% | ||
| Current month | -15.50% | ||
| 1 month | +13.23% | ||
| 3 months | -15.01% | ||
| 6 months | -36.14% | ||
| Current year | -34.87% |
| 1 week | 12.36 |  | 16.2 |
| 1 month | 7.05 | | 18.2 |
| Current year | 7.05 | | 24.4 |
| 1 year | 7.05 | | 25.3 |
| 3 years | 4.98 | | 124.6 |
| 5 years | 4.98 | | 146 |
| 10 years | 4.75 | | 146 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jeppe Øvlesen
CEO | Chief Executive Officer | 64 | 01/01/2014 |
Ann Kristin Led
DFI | Director of Finance/CFO | - | 01/03/2026 |
Kirsten Harting
CTO | Chief Tech/Sci/R&D Officer | - | 15/02/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Jeppe Øvlesen
BRD | Director/Board Member | 64 | 20/03/2024 |
Anders Kronborg
CHM | Chairman | 62 | 20/03/2024 |
Sten Scheibye
BRD | Director/Board Member | 74 | 20/03/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 03-10 | Buy | Chairman | 2,750 | 0.0052% | ||
| 03-09 | Buy | Executive/Senior Manager | 1,500 | 0.0028% | ||
| 03-09 | Quantass ApS
| Buy | Company | 7,900 | 0.0148% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.26% | +26.24% | -16.74% | -79.50% | 82.12M | |
| +0.92% | +0.47% | +43.59% | +143.50% | 996B | |
| +0.80% | +2.90% | +58.35% | +45.64% | 580B | |
| +0.06% | +6.17% | +26.59% | +72.81% | 415B | |
| +3.89% | -2.44% | +22.01% | +15.66% | 326B | |
| -0.13% | +5.18% | +30.69% | +39.63% | 280B | |
| +0.29% | +5.98% | +36.03% | +23.45% | 284B | |
| +1.19% | +12.73% | -27.46% | -41.26% | 210B | |
| +1.27% | +2.86% | +26.65% | +54.74% | 190B | |
| +0.09% | -0.23% | +16.75% | +61.56% | 155B | |
| Average | +0.48% | +6.54% | +21.65% | +33.62% | 343.68B | |
| Weighted average by Cap. | +0.71% | +2.18% | +33.82% | +68.04% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 139M 14.22M 12.52M 11.55M 10.8M 20.23M 1.34B 20.61M 53.74M 661M 53.38M 52.22M 2.3B | 21.15M 2.17M 1.91M 1.76M 1.65M 3.08M 204M 3.14M 8.19M 101M 8.14M 7.96M 351M |
| Net income | 52.18M 5.35M 4.71M 4.34M 4.06M 7.61M 504M 7.75M 20.21M 249M 20.07M 19.64M 865M | -26.04M -2.67M -2.35M -2.17M -2.03M -3.8M -252M -3.87M -10.09M -124M -10.02M -9.8M -432M |
| Net Debt | -17.48M -1.79M -1.58M -1.45M -1.36M -2.55M -169M -2.6M -6.77M -83.28M -6.72M -6.58M -290M | 24.86M 2.55M 2.24M 2.07M 1.93M 3.63M 240M 3.69M 9.63M 118M 9.56M 9.36M 412M |
Employees
8
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 25/06/26 | SEK 14.72 | -2.26% | 136,179 |
| 24/06/26 | SEK 15.06 | -0.92% | 265,235 |
| 23/06/26 | SEK 15.20 | +2.01% | 454,040 |
| 22/06/26 | SEK 14.90 | +27.79% | 775,261 |
| 18/06/26 | SEK 11.66 | +9.38% | 517,062 |
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SYNACT Stock
Select your edition
All financial news and data tailored to specific country editions
